This presentation does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the matters or entities described herein. Recipients are responsible for conducting their own investigations and analyses of Optimi and the information contained or referred to herein and should not act solely on the basis of any information contained or referred to in this presentation. No representation or warranty, express or implied, is given and no responsibility or liability is accepted by any person, with respect to the accuracy, fairness or completeness of this presentation or its contents or any oral or written communication in connection with any matter described herein.
This presentation does not constitute and should not be construed as, an advertisement, public offering, prospectus, offering memorandum or an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company in Canada, the United States or any other jurisdiction. No securities commission or similar authority has reviewed or in any way passed upon this presentation, and any representation to the contrary is an offence. Any offer to sell or solicitation of an offer to buy securities will be made only by means of a prospectus that meets the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
This presentation contains forward-looking statements that relate to Optimi's current expectations and views of future events. Statements that express or involve discussions as to expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct.
Market data and certain industry data and forecasts included in this presentation were obtained from internal company surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. Optimi has not independently verified any of the data from third-party sources. This presentation is confidential and is being provided solely for your information; by accepting it, you agree to keep it confidential and not to use it for any purpose other than to evaluate a potential investment in Optimi.
Follow-on equity offering and initial Nasdaq listing.
| Issuer | Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF) |
| Proposed Listing | NASDAQ: OPTH |
| Offering Type | Follow-On Offering; Initial Listing on Nasdaq |
| Securities Offered | Common Stock |
| Offering Price | $6.00 – $8.00 per share |
| Offering Size | 2,142,857 shares of common stock, excl. 15% over-allotment option* |
| Shares Out (Pre) | 3,233,333 shares** |
| Shares Out (Post) | 5,108,333 – 5,733,333; 5,389,583 – 6,108,333 (full over-allotment)** |
| Use of Proceeds | Commercial business development and product distribution; general working capital |
| Lockup | 180 days |
| Expected Pricing | March 2026 |
| Sole Book-Running Manager | Joseph Gunnar & Co., LLC |
Allocation for proposed USD $15.0M offering.
Positioned to take advantage of the rescheduling revolution shaping the market of tomorrow.
Optimi's GMP-compliant MDMA and psilocybin products are already reaching patients under Australia's Authorized Prescriber Scheme.
Patient-reported outcomes are being collected across both products, creating an extensive clinical data set.
With legally-permitted MDMA and psilocybin under active review worldwide, Optimi is positioned to supply new markets as they open.
Purpose-built, Health Canada-licensed facilities ensure compliance and scalable production for any future market.
While others remain in costly, multi-year trials, Optimi is commercial today — building sales channels and market share.
Legacy options — SSRIs, benzos, psychotherapy — reflect limited efficacy and high relapse.
Contributing factorsModern lifestyle pressures, digital and social media overload, increasing loneliness and social isolation, socioeconomic pressures, and AI-driven labor displacement.
“Australian psychiatrists are now prescribing Optimi's GMP-compliant MDMA and psilocybin capsules for therapeutic use. Having two regulated psychedelic drug products reaching clinics and patients is a significant milestone for the company and the industry.”
Global MDMA access is accelerating. Optimi is actively supplying patients in Australia, Canada, and Israel — with hundreds treated to date.
Optimi's proprietary natural psilocybin extract capsule is already reaching patients in Australia.
August 2025 marked the launch of Optimi's psilocybin drug product in Australia.
As with ketamine and cannabis, the global MDMA & psilocybin market will emerge through rescheduling — driven by cost-efficient medicine, GMP manufacturing, and scalable direct-to-clinic distribution.
The US rescheduling journey could follow Australia's, with Optimi's strategy combining its proven playbook and learnings from J&J's Spravato ketamine commercialization or cannabis rescheduling in the US.
In the US, J&J's Spravato has scaled rapidly — 6,800+ certified clinics, 46,000+ monthly prescriptions, and annual sales exceeding $1B, growing 50%+ YoY. Generic ketamine remains widely used in parallel — a dual-track market where branded and non-branded products both achieve adoption.
Optimi is well positioned to supply jurisdictions that open a regulated framework.
Rescheduling is a government classification that determines whether a drug has an accepted medical use. As a GMP manufacturer, Optimi is positioned to supply any new market.
“Everybody in my agency — and over at [Secretary Doug Collins's] agency — is very anxious to get a rule out there that will allow these kinds of studies and will allow access under therapeutic settings. We're working through that process now.”
“I think that we're going to get it done.”
The Trump administration has shown significant interest in accelerating psychedelic-assisted therapy.
“This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months.”Health Secretary Robert F. Kennedy Jr. to Members of Congress · July 2025
Nearly 5,000 total doses shipped globally as of Q1 2026; repeat orders scaling with distribution partners in Australia; capacity to manufacture millions of doses for export.
Finished drug products shipped from Health Canada-licensed GMP facility.
In-country logistics partners handle last-mile delivery to qualified clinics.
Authorised prescribers administer MDMA or psilocybin-assisted therapy.
DVA and other programs close the loop; patient-reported outcomes feed back in.
Australia is the proof-of-concept market. The United States — once rescheduled — represents a step-change in addressable demand roughly 23× larger in combined PTSD and TRD populations.
Psychedelic company market caps and current drugs in-market — January 2026.
| Optimi | Resilience | atai | Definium | Compass | Helus | |
|---|---|---|---|---|---|---|
| Market cap¹ | $22M | N/A | $1.6B | $1.9B | $829M | $287M |
| MDMA in market | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Psilocybin in market | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Insurance reimbursement | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Drug Establishment License (Health Canada) | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
Executives, directors, and strategic advisors who built and scaled global consumer and pharmaceutical brands.
Serial entrepreneur who built a $50B+ global athletic apparel brand.
Nutritionist; Master's in Exercise Physiology, University of Toronto.
The trusted manufacturer of choice for emerging psychedelic-based mental health treatments.
Drug Establishment License from Health Canada to export psychedelic finished drug products for any allowable indication.
Optimi's MDMA and psilocybin are actively being exported for use in qualified clinics, with licensed entities conducting clinical trials globally.
MDMA and psilocybin have growing clinical evidence for use in the $12B global anxiety disorders treatment market.
Facilities ready to scale production with new market opportunities.
With patients now using MDMA and psilocybin in Special Access Programs, countries including the US are moving toward rescheduling.
Competition is focused on clinical development; Optimi is focused on establishing sales channels and increasing market share.
Health Canada-licensed. GMP-compliant. Purpose-built for MDMA and psilocybin at scale.